Skip to main content
. 2021 Aug 18;11:701539. doi: 10.3389/fonc.2021.701539

Table 5.

Treatment-related adverse events.

Eltrombopag (N=51) rhTPO (N=50)
Any AE, n (%) 7 (13.7) 6 (12.0)
 Elevated transaminase 3 (5.9) 0 (0.0)
 Hyperbilirubinemia 1 (2.0) 0 (0.0)
 Fever 1 (2.0) 2 (4.0)
 Fatigue 1 (2.0) 1 (2.0)
 Dizziness 1 (2.0) 1 (2.0)
 Diarrhea 0 (0.0) 1 (2.0)
 Muscle aches 0 (0.0) 1 (2.0)